601 related articles for article (PubMed ID: 23600548)
1. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis.
Didier A; Malling HJ; Worm M; Horak F; Sussman G; Melac M; Soulié S; Zeldin RK
Clin Exp Allergy; 2013 May; 43(5):568-77. PubMed ID: 23600548
[TBL] [Abstract][Full Text] [Related]
2. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE.
Cox LS; Casale TB; Nayak AS; Bernstein DI; Creticos PS; Ambroisine L; Melac M; Zeldin RK
J Allergy Clin Immunol; 2012 Dec; 130(6):1327-34.e1. PubMed ID: 23122534
[TBL] [Abstract][Full Text] [Related]
4. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
5. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
6. Five-grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents.
Halken S; Agertoft L; Seidenberg J; Bauer CP; Payot F; Martin-Muñoz MF; Bartkowiak-Emeryk M; Vereda A; Jean-Alphonse S; Melac M; Le Gall M; Wahn U
Pediatr Allergy Immunol; 2010 Sep; 21(6):970-6. PubMed ID: 20718927
[TBL] [Abstract][Full Text] [Related]
7. 300IR 5-Grass pollen sublingual tablet offers relief from nasal symptoms in patients with allergic rhinitis.
Serrano E; Wahn HU; Didier A; Bachert C
Am J Rhinol Allergy; 2014; 28(6):471-6. PubMed ID: 25335122
[TBL] [Abstract][Full Text] [Related]
8. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy.
Didier A; Melac M; Montagut A; Lhéritier-Barrand M; Tabar A; Worm M
Allergy; 2009 Jan; 64(1):166-71. PubMed ID: 19076546
[TBL] [Abstract][Full Text] [Related]
9. Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment.
Horak F; Jaeger S; Worm M; Melac M; Didier A
Clin Exp Allergy; 2009 Mar; 39(3):394-400. PubMed ID: 19134018
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.
Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F
J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937
[TBL] [Abstract][Full Text] [Related]
11. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
Dahl R; Stender A; Rak S
Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
[TBL] [Abstract][Full Text] [Related]
12. [Sublingual immunotherapy in children with grass pollen induced allergic rhinoconjunctivitis].
Wolthers OD; Høst A; Frederiksen B; Halken S
Ugeskr Laeger; 2012 Aug; 174(35):1989-92. PubMed ID: 22929576
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study.
Ott H; Sieber J; Brehler R; Fölster-Holst R; Kapp A; Klimek L; Pfaar O; Merk H
Allergy; 2009 Sep; 64(9):1394-401. PubMed ID: 19764942
[TBL] [Abstract][Full Text] [Related]
14. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study.
Hordijk GJ; Antvelink JB; Luwema RA
Allergol Immunopathol (Madr); 1998; 26(5):234-40. PubMed ID: 9885731
[TBL] [Abstract][Full Text] [Related]
15. The relevance of patient-reported outcomes in a grass pollen immunotherapy trial in children and adolescents with rhinoconjunctivitis.
Röder E; Berger MY; Hop WC; de Groot H; van Wijk RG
Pediatr Allergy Immunol; 2013 Feb; 24(1):39-48. PubMed ID: 22882319
[TBL] [Abstract][Full Text] [Related]
16. SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis.
Dahl R; Roberts G; de Blic J; Canonica GW; Kleine-Tebbe J; Nolte H; Lawton S; Nelson HS
Allergy Asthma Proc; 2016; 37(2):92-104. PubMed ID: 26802643
[TBL] [Abstract][Full Text] [Related]
17. Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy.
Van Overtvelt L; Baron-Bodo V; Horiot S; Moussu H; Ricarte C; Horak F; Zieglmayer P; Zieglmayer R; Montagut A; Galvain S; de Beaumont O; Le Gall M; Moingeon P
Allergy; 2011 Dec; 66(12):1530-7. PubMed ID: 21883279
[TBL] [Abstract][Full Text] [Related]
18. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.
Rolinck-Werninghaus C; Wolf H; Liebke C; Baars JC; Lange J; Kopp MV; Hammermann J; Leupold W; Bartels P; Gruebl A; Bauer CP; Schnitker J; Wahn U; Niggemann B
Allergy; 2004 Dec; 59(12):1285-93. PubMed ID: 15507097
[TBL] [Abstract][Full Text] [Related]
19. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
[TBL] [Abstract][Full Text] [Related]
20. Conjunctival provocation tests: a predictive factor for patients' seasonal allergic rhinoconjunctivitis symptoms.
Kruse K; Gerwin E; Eichel A; Shah-Hosseini K; Mösges R
J Allergy Clin Immunol Pract; 2015; 3(3):381-6. PubMed ID: 25609338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
